172 related articles for article (PubMed ID: 35593203)
1. Mas-related G protein-coupled receptor type D antagonism improves portal hypertension in cirrhotic rats.
Gunarathne LS; Rajapaksha IG; Casey S; Qaradakhi T; Zulli A; Rajapaksha H; Trebicka J; Angus PW; Herath CB
Hepatol Commun; 2022 Sep; 6(9):2523-2537. PubMed ID: 35593203
[TBL] [Abstract][Full Text] [Related]
2. Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats.
Gunarathne LS; Angus PW; Herath CB
Front Physiol; 2019; 10():1169. PubMed ID: 31607942
[TBL] [Abstract][Full Text] [Related]
3. Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis.
Grace JA; Klein S; Herath CB; Granzow M; Schierwagen R; Masing N; Walther T; Sauerbruch T; Burrell LM; Angus PW; Trebicka J
Gastroenterology; 2013 Oct; 145(4):874-884.e5. PubMed ID: 23796456
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome analysis of mesenteric arterioles changes and its mechanisms in cirrhotic rats with portal hypertension.
Wu G; Chen M; Fan Q; Li H; Zhao Z; Zhang C; Luo M
BMC Genomics; 2023 Jan; 24(1):20. PubMed ID: 36641445
[TBL] [Abstract][Full Text] [Related]
5. Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options.
Rajapaksha IG; Gunarathne LS; Angus PW; Herath CB
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33670126
[TBL] [Abstract][Full Text] [Related]
6. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics.
Gunarathne LS; Rajapaksha H; Shackel N; Angus PW; Herath CB
World J Gastroenterol; 2020 Oct; 26(40):6111-6140. PubMed ID: 33177789
[TBL] [Abstract][Full Text] [Related]
7. Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.
Cavasin MA; Semus H; Pitts K; Peng Y; Sandoval J; Chapo J; Plato CF
Can J Physiol Pharmacol; 2010 Jun; 88(6):636-43. PubMed ID: 20628429
[TBL] [Abstract][Full Text] [Related]
8. The beneficial effects of curcumin in cirrhotic rats with portal hypertension.
Hsu SJ; Lee JY; Lin TY; Hsieh YH; Huang HC; Lee FY; Lin HC; Hou MC; Lee SD
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29162665
[TBL] [Abstract][Full Text] [Related]
9. Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats.
Königshofer P; Brusilovskaya K; Schwabl P; Podesser BK; Trauner M; Reiberger T
J Vis Exp; 2018 Aug; (138):. PubMed ID: 30124644
[TBL] [Abstract][Full Text] [Related]
10. Gender differences in vascular reactivity of mesenteric arterioles in portal hypertensive and non-portal hypertensive rats.
Zhang B; Ji LH; Zhang CG; Zhao G; Wu ZY
World J Gastroenterol; 2019 Oct; 25(39):5953-5960. PubMed ID: 31660032
[TBL] [Abstract][Full Text] [Related]
11. Cediranib ameliorates portal hypertensive syndrome via inhibition of VEGFR-2 signaling in cirrhotic rats.
Fan Q; Wu G; Chen M; Luo G; Wu Z; Huo H; Li H; Zheng L; Luo M
Eur J Pharmacol; 2024 Feb; 964():176278. PubMed ID: 38158116
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.
Trebicka J; Leifeld L; Hennenberg M; Biecker E; Eckhardt A; Fischer N; Pröbsting AS; Clemens C; Lammert F; Sauerbruch T; Heller J
Hepatology; 2008 Apr; 47(4):1264-76. PubMed ID: 18318439
[TBL] [Abstract][Full Text] [Related]
13. Microbiota transplants from feces or gut content attenuated portal hypertension and portosystemic collaterals in cirrhotic rats.
Huang HC; Tsai MH; Chang CC; Pun CK; Huang YH; Hou MC; Lee FY; Hsu SJ
Clin Sci (Lond); 2021 Dec; 135(24):2709-2728. PubMed ID: 34870313
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
[TBL] [Abstract][Full Text] [Related]
15. Dual angiotensin receptor and neprilysin inhibitor reduced portal pressure through peripheral vasodilatation and decreasing systemic arterial pressure in cirrhotic rats.
Pun CK; Chang CC; Chuang CL; Huang HC; Hsu SJ; Huang YH; Hou MC; Lee FY
J Chin Med Assoc; 2023 Sep; 86(9):786-794. PubMed ID: 37462441
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction.
Moleda L; Trebicka J; Dietrich P; Gäbele E; Hellerbrand C; Straub RH; Sauerbruch T; Schoelmerich J; Wiest R
Gut; 2011 Aug; 60(8):1122-32. PubMed ID: 21317421
[TBL] [Abstract][Full Text] [Related]
17. Contribution of Splenic Resistance Arteries to Splanchnic Blood Overflow in Cirrhosis.
Turkseven S; Bolognesi M; Di Pascoli M
Dig Dis Sci; 2021 Mar; 66(3):796-801. PubMed ID: 32242304
[TBL] [Abstract][Full Text] [Related]
18. Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension.
Tsai HC; Li TH; Huang CC; Huang SF; Liu RS; Yang YY; Hsieh YC; Lee KC; Huang YH; Hou MC; Lin HC
Am J Pathol; 2018 Jul; 188(7):1608-1624. PubMed ID: 29929914
[TBL] [Abstract][Full Text] [Related]
19. Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats.
Heller J; Shiozawa T; Trebicka J; Hennenberg M; Schepke M; Neef M; Sauerbruch T
Eur J Clin Invest; 2003 Nov; 33(11):1006-12. PubMed ID: 14636305
[TBL] [Abstract][Full Text] [Related]
20. DPP4 inhibitor reduces portal hypertension in cirrhotic rats by normalizing arterial hypocontractility.
Wang X; Gu H; Li K; Lin J; Zhu Y; Deng W
Life Sci; 2021 Nov; 284():119895. PubMed ID: 34450166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
